Development of Carboxyfullerene Drugs to Treat ALS

治疗 ALS 的羧基富勒烯药物的开发

• 批准号: 6666951
• 负责人: JOHN M ALFORD
• 金额: $ 39.89万
• 依托单位: TDA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6666951
• 关键词: Parkinson's disease; amyotrophic lateral sclerosis; antioxidants; drug design /synthesis /production; free radical scavengers; liquid chromatography; method development; neuropharmacologic agent; neuroprotectants

DESCRIPTION (provided by applicant): Studies show that fullerene-based antioxidants make excellent neuroprotectants, and they have demonstrated good efficacy in models for a wide array of oxidative neurological disorders including arnyotrophic lateral sclerosis (ALS), Parkinson's disease and brain injury resulting from ischemic stroke. These results suggest that neuroprotective pharmaceuticals are one of the most unique, yet important and commercially viable applications of fullerenes to date. Although it shows great promise as a neuroprotectant drug useful in treating ailments such as ALS and Parkinson's disease for which better treatments are desperately needed, the derivatized fullerene compounds are currently too expensive and cannot be produced in sufficient quantities for clinical testing or to treat patients. During Phase I, we developed several new techniques that allow efficient production of a carboxyfullerene pharmaceutical compound. With continued development, we anticipate that by the completion of the project, it will be possible to economically manufacture enough of the fullerene- based neuroprotectant for clinical trials to begin.

描述（由申请人提供）：研究表明，基于富勒烯的抗氧化剂是优异的神经保护剂，并且它们在多种氧化神经系统疾病模型中表现出良好的功效，包括肌萎缩侧索硬化症（ALS）、帕金森病和缺血性中风引起的脑损伤。这些结果表明，神经保护药物是迄今为止富勒烯最独特、最重要且商业上可行的应用之一。 尽管它作为一种神经保护药物显示出巨大的前景，可用于治疗急需更好治疗的 ALS 和帕金森氏病等疾病，但衍生的富勒烯化合物目前过于昂贵，并且无法大量生产用于临床测试或治疗患者。在第一阶段，我们开发了几种新技术，可以有效生产羧基富勒烯药物化合物。随着不断的发展，我们预计该项目完成后，将有可能经济地生产足够的基于富勒烯的神经保护剂，用于临床试验的开始。